First, we demonstrated that PD-L1 overexpression in lung cancer is associated with increased sensitivity to EGFR inhibitors, and a higher expression of EGFR and genes critical to neo-antigen presentation, and that down-modulation of PD-L1 may be an additional mechanism of anti-tumor activity of EGFR inhibitors in augmenting anti-tumor T cell responses. The gene discussed is EGFR; the disease is lung carcinoma.